Plasma Level of Elabela in Patients with Coronary Heart Disease and Its Correlation with the Disease Classification

Area of Science:

• Cardiology
• Endocrinology
• Biochemistry

Background:

• Coronary heart disease (CHD) poses a significant global health challenge.
• Biomarkers for assessing CHD severity and progression are crucial for patient management.
• The role of novel hormones, such as elabela (ELA), in cardiovascular disease requires further investigation.

Purpose of the Study:

• To evaluate plasma elabela (ELA) concentrations in patients with coronary heart disease (CHD).
• To assess the correlation between ELA levels and CHD classification (stable angina, unstable angina, acute myocardial infarction).

Main Methods:

• Plasma ELA levels were measured in 238 CHD patients and 86 controls.
• CHD patients were categorized into stable angina (SA), unstable angina (UAP), and acute myocardial infarction (AMI) subgroups.
• Statistical analyses were performed to compare ELA levels among groups and correlate them with clinical variables.

Main Results:

• Plasma ELA levels were significantly higher in CHD patients compared to controls (10.71% increase, P < 0.05).
• ELA concentrations were elevated in UAP and AMI subgroups compared to controls and the SA subgroup (P < 0.05 for UAP/AMI vs. controls).
• ELA levels did not correlate with SYNTAX score, left ventricular ejection fraction, or other biochemical variables.

Conclusions:

• Plasma ELA is significantly elevated in patients experiencing acute coronary syndromes (UAP and AMI).
• ELA levels show a potential correlation with CHD classification, suggesting a role in acute phases of the disease.
• ELA may serve as a potential biomarker for acute coronary events, independent of lesion severity.